HomeNewsBusinessEarningsIdeas For Profit | Is growing demand for personal hygiene products a game-changer for Galaxy Surfactants?

Ideas For Profit | Is growing demand for personal hygiene products a game-changer for Galaxy Surfactants?

Watch the video to find out if investors should keep an eye on Galaxy Surfactants' stock

June 30, 2020 / 14:23 IST
Story continues below Advertisement

Galaxy Surfactants, the leading oleochemical maker, posted a relatively steady quarter with positive volume growth and improving margin profile. The company with its range of products which find applications in the Home and Personal Care (HPC) category is seen as a key beneficiary of the surge in demand for personal and household hygiene needs.

As a leading market share in the domestic surfactant market and a high proportion of revenue exposure to MNCs (55 percent of sales), the company merits attention due to relatively better earnings visibility in the Chemicals space. Having said that heightened competitive intensity, uncertain environment for both demand & supply and a long drawn phase of downtrading/lower discretionary spending comes up as key risks to watch.

Story continues below Advertisement

Watch the video to find out if it is worthy of being kept on your radar as a key beneficiary of growing demand in hygiene products.

 

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show
Moneycontrol News
first published: Jun 30, 2020 02:23 pm

Disclosure & Disclaimer

This Research Report / Research Recommendation has been published by Moneycontrol Dot Com India Limited (hereinafter referred to as “MCD”) which is a registered Investment Advisor under the Securities and Exchange Board of India (Investment Advisers) ...Read More

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!